BeyondSpring (BYSI)
(Delayed Data from NSDQ)
$2.13 USD
-0.08 (-3.62%)
Updated Sep 20, 2024 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
BeyondSpring Inc. [BYSI]
Reports for Purchase
Showing records 1 - 20 ( 67 total )
Company: BeyondSpring Inc.
Industry: Medical - Biomedical and Genetics
Company: BeyondSpring Inc.
Industry: Medical - Biomedical and Genetics
Company: BeyondSpring Inc.
Industry: Medical - Biomedical and Genetics
Reports 1Q22, $17M in Cash but Shares Rise to 20M, Which Lowers Our Target Valuation from $10.0 to $8.0
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: BeyondSpring Inc.
Industry: Medical - Biomedical and Genetics
2021 Results; Priority Remains Progressing Plinabulin Regulatory Activities With Focus on China
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BeyondSpring Inc.
Industry: Medical - Biomedical and Genetics
Neutral Rated; $91.6M in Cash ? What?s Next: China?
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: BeyondSpring Inc.
Industry: Medical - Biomedical and Genetics
Hunkering Down for Cash Preservation Ahead of FDA Interactions; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BeyondSpring Inc.
Industry: Medical - Biomedical and Genetics
Neutral Rated; $91.6M in Cash ? What?s Next: China?
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: BeyondSpring Inc.
Industry: Medical - Biomedical and Genetics
3Q21 Results; Regulatory Advancement of Plinabulin for CIN Remains the Main Focus
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BeyondSpring Inc.
Industry: Medical - Biomedical and Genetics
Company: BeyondSpring Inc.
Industry: Medical - Biomedical and Genetics
CRL Puts Timing and Thesis Up in Air; Downgrade to Neutral, Removing PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BeyondSpring Inc.
Industry: Medical - Biomedical and Genetics
SCLC Phase 2 Gets Going; CIN PDUFA Next Month; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BeyondSpring Inc.
Industry: Medical - Biomedical and Genetics
Company: BeyondSpring Inc.
Industry: Medical - Biomedical and Genetics
Totality of DUBLIN-3 Data Encouraging; Investors Continue to Assess; Target Reduced to $65
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BeyondSpring Inc.
Industry: Medical - Biomedical and Genetics
2Q21 Results; A Little Reminder, Plinabulin Has Breakthrough Therapy Designation and Priority Review
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BeyondSpring Inc.
Industry: Medical - Biomedical and Genetics
Key 2021 Universe Catalysts to Focus On as Market Turbulence Continues
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BeyondSpring Inc.
Industry: Medical - Biomedical and Genetics
Plinabulin?s Global Commercialization Plans Strengthen With Partnership; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BeyondSpring Inc.
Industry: Medical - Biomedical and Genetics
Company: BeyondSpring Inc.
Industry: Medical - Biomedical and Genetics
Our 0.500 Batting Average Is Hall of Fame Worthy; Here, Patients Win 100%; Upgrade to Buy and $100 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BeyondSpring Inc.
Industry: Medical - Biomedical and Genetics
R&D Day Highlights Plinabulin''s Anti-Cancer Activity Potential
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: BeyondSpring Inc.
Industry: Medical - Biomedical and Genetics
1Q21 Results; CIN Priority Review Should Be Smooth Ride, But We Are Quite Cautious on Imminent Phase 3 NSCLC Data
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J